Identification of Residual Breast Carcinoma Following Neoadjuvant Chemotherapy: Diffusion-weighted Imaging—Comparison with Contrast-enhanced MR Imaging and Pathologic Findings

Abstract

DW MR imaging had at least as good of accuracy as did contrast-enhanced MR imaging for monitoring neoadjuvant chemotherapy. The ADCs prior to chemotherapy did not predict response to chemotherapy. The use of DW imaging to visualize residual breast cancer without the need for contrast medium could be advantageous in women with impaired renal function.